TY - JOUR
T1 - Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-associated HLA-B*51 Peptidome
AU - Guasp, Pablo
AU - Lorente, Elena
AU - Martín-Esteban, Adrian
AU - Barnea, Eilon
AU - Romania, Paolo
AU - Fruci, Doriana
AU - Kuiper, Jonas J.W.
AU - Admon, Arie
AU - López de Castro, José A.
N1 - Funding Information:
* Supported by grants SAF2017/86578-R (Plan Nacional de I+D+i) to José A. López de Castro, Israel Science Foundation, grant N. 1435/16 to Arie Admon, and an institutional grant of the Fundación Ramón Areces to the Centro de Biología Molecular Severo Ochoa. Doriana Fruci is supported by grants from the Italian Ministry of Health (PE-2011-02351866) and the Associazione Italiana Ricerca sul Can-cro (AIRC: grant N. 18495). Jonas J. W. Kuiper is supported by a VENI award from the Netherlands Organization for Scientific Research (N.W.O. project number 016.186.006). Pablo Guasp and Elena Lorente are recipients of FPI (BES-2015-072729) and Juan de la Cierva (FJCI-2016-28335) awards from the Government of SPAIN, respectively. □S This article contains supplemental Figures and Tables. ** To whom correspondence should be addressed: Centro de Bi-ología Molecular Severo Ochoa, c/Nicolás Cabrera, N. 1, Universidad Autónoma, 28049 Madrid, Spain. Tel.: 34-91 196 4554; E-mail: [email protected].
Publisher Copyright:
© 2019 Guasp et al.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - The endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 trim peptides to be loaded onto HLA molecules, including the main risk factor for Behçet’s disease HLA-B*51. ERAP1 is also a risk factor among HLA-B*51-positive individuals, whereas no association is known with ERAP2. This study addressed the mutual relationships between both enzymes in the processing of an HLA-bound peptidome, interrogating their differential association with Behçet’s disease. CRISPR/Cas9 was used to generate knock outs of ERAP1, ERAP2 or both from transfectant 721.221-HLA-B*51:01 cells. The surface expression of HLA-B*51 was reduced in all cases. The effects of depleting each or both enzymes on the B*51:01 peptidome were analyzed by quantitative label-free mass spectrometry. Substantial quantitative alterations of peptide length, subpeptidome balance, N-terminal residue usage, affinity and presentation of noncanonical ligands were observed. These effects were often different in the presence or absence of the other enzyme, revealing their mutual dependence. In the absence of ERAP1, ERAP2 showed similar and significant processing of B*51:01 ligands, indicating functional redundancy. The high overlap between the peptidomes of wildtype and double KO cells indicates that a large majority of B*51:01 ligands are present in the ER even in the absence of ERAP1/ERAP2. These results indicate that both enzymes have distinct, but complementary and partially redundant effects on the B*51:01 peptidome, leading to its optimization and maximal surface expression. The distinct effects of both enzymes on the HLA-B*51 peptidome provide a basis for their differential association with Behçet’s disease and suggest a pathogenetic role of the B*51:01 peptidome.We thank Prof. Masafumi Takiguchi (Center for AIDS Research, Kumamoto University, Kumamato, Japan) for kindly providing HLA-B*51:01 transfectant cells and Sanne Hiddingh (Laboratory of Translational Immunology, University Medical Center, Utrecht University, The Netherlands) for her technical support in the generation of the KO cell lines.
AB - The endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 trim peptides to be loaded onto HLA molecules, including the main risk factor for Behçet’s disease HLA-B*51. ERAP1 is also a risk factor among HLA-B*51-positive individuals, whereas no association is known with ERAP2. This study addressed the mutual relationships between both enzymes in the processing of an HLA-bound peptidome, interrogating their differential association with Behçet’s disease. CRISPR/Cas9 was used to generate knock outs of ERAP1, ERAP2 or both from transfectant 721.221-HLA-B*51:01 cells. The surface expression of HLA-B*51 was reduced in all cases. The effects of depleting each or both enzymes on the B*51:01 peptidome were analyzed by quantitative label-free mass spectrometry. Substantial quantitative alterations of peptide length, subpeptidome balance, N-terminal residue usage, affinity and presentation of noncanonical ligands were observed. These effects were often different in the presence or absence of the other enzyme, revealing their mutual dependence. In the absence of ERAP1, ERAP2 showed similar and significant processing of B*51:01 ligands, indicating functional redundancy. The high overlap between the peptidomes of wildtype and double KO cells indicates that a large majority of B*51:01 ligands are present in the ER even in the absence of ERAP1/ERAP2. These results indicate that both enzymes have distinct, but complementary and partially redundant effects on the B*51:01 peptidome, leading to its optimization and maximal surface expression. The distinct effects of both enzymes on the HLA-B*51 peptidome provide a basis for their differential association with Behçet’s disease and suggest a pathogenetic role of the B*51:01 peptidome.We thank Prof. Masafumi Takiguchi (Center for AIDS Research, Kumamoto University, Kumamato, Japan) for kindly providing HLA-B*51:01 transfectant cells and Sanne Hiddingh (Laboratory of Translational Immunology, University Medical Center, Utrecht University, The Netherlands) for her technical support in the generation of the KO cell lines.
KW - Behçet's disease
KW - ERAP1
KW - ERAP2
KW - HLA-B51
KW - Immunology
KW - Inflammation
KW - Label-free quantification
KW - Mass Spectrometry
KW - MHC
KW - Peptides
UR - http://www.scopus.com/inward/record.url?scp=85071055100&partnerID=8YFLogxK
U2 - 10.1074/mcp.RA119.001515
DO - 10.1074/mcp.RA119.001515
M3 - Article
C2 - 31092671
AN - SCOPUS:85071055100
SN - 1535-9476
VL - 18
SP - 1491
EP - 1510
JO - Molecular & cellular proteomics : MCP
JF - Molecular & cellular proteomics : MCP
IS - 8
ER -